ImmuNext
ImmuNext appears to be a dormant or wound-down entity, historically associated with Lebanon, New Hampshire, with no active web presence, disclosed products, or operational data available in current sources.
- Company typePrivate
- Founded2011
- HeadquartersLebanon, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
ImmuNext firmographics
Firmographics- Name
- ImmuNext
- Website
- https://immunext.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 11–50 employees
- Short description
- ImmuNext appears to be a dormant or wound-down entity, historically associated with Lebanon, New Hampshire, with no active web presence, disclosed products, or operational data available in current sources.
- Ownership category
- akta.pro rank
ImmuNext industry classification
Industry- Product category
- Biotechnology
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where ImmuNext is headquartered
LocationHeadquarters
- HQ city
- Lebanon
- HQ country
- United States
- HQ region
- North America
Markets served
ImmuNext business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Others
ImmuNext product offering
Product offeringCore offering
ImmuNext has no publicly documented core offering. The company's domain (immunext.com) is currently parked by GoDaddy as a registrar landing page, and no information about products, services, or business activities is available from the source data.
Differentiator
Problem solved
Functional benefit
Companies that use ImmuNext
Customer profileIdeal customer profiles1 record
ImmuNext technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ImmuNext competitors and assessment
Company assessmentDirect peers
- Compass Therapeutics: Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Comparable on antibody platform development and immuno-oncology focus.
- Adimab: Adimab is a Lebanon, NH-based antibody discovery platform that engineers therapeutic antibodies for partners. It is the most directly comparable peer to ImmuNext given the shared Lebanon, NH geography and the antibody/immunology orientation implied by the 'ImmuNext' name.
- Adagene: Adagene is a clinical-stage biopharmaceutical company with a pipeline of immuno-oncology antibody therapeutics powered by its proprietary platform. It is a relevant immunology antibody peer.
- AnaptysBio: AnaptysBio is a clinical-stage biotechnology company developing antibody-based therapeutics for inflammation and immuno-oncology. Comparable to ImmuNext on antibody/immunology focus and clinical-stage scale.
- MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for cancer and autoimmune disease. It is a relevant antibody/immunology peer for an ImmuNext-type biotech.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron is a leading biopharmaceutical company with a substantial antibody therapeutics franchise anchored by its VelocImmune platform. It serves as a broad incumbent comparable to any antibody-focused biotech.
- Moderna: Moderna is a commercial-stage biotech with broader immunology-related programs spanning infectious disease and oncology. It is a major Northeast-based biotech incumbent relevant to any immunology-oriented peer.
Emerging players
- Werewolf Therapeutics: Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics designed to target the tumor microenvironment. It represents an emerging peer in the immuno-oncology space.
- Scholar Rock: Scholar Rock is a clinical-stage biopharmaceutical company developing innovative biologics targeting supracellular activation of growth factors, with applications in serious disease. It represents an emerging immunology/biologics peer.
- Surface Oncology: Surface Oncology is a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment. It is a relevant emerging immunology biotech peer.
Market position
Customer concentration
ImmuNext social profiles
Digital presenceImmuNext financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmuNext leadership team
Management profileNumber of profiles
ImmuNext funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmuNext M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmuNext
What does ImmuNext do?
ImmuNext has no publicly documented core offering. The company's domain (immunext.com) is currently parked by GoDaddy as a registrar landing page, and no information about products, services, or business activities is available from the source data.
When was ImmuNext founded?
ImmuNext was founded in 2011. It employs 11 to 50 people.
Where is ImmuNext based?
ImmuNext is headquartered in Lebanon, United States, in the North America region.
Who are ImmuNext's main competitors?
Direct peers on record are Compass Therapeutics, Adimab, Adagene, AnaptysBio and MacroGenics. Broad incumbents are Regeneron Pharmaceuticals and Moderna. Emerging players are Werewolf Therapeutics, Scholar Rock and Surface Oncology.
Does ImmuNext have an API?
No public API is recorded for ImmuNext.
What industry is ImmuNext in?
ImmuNext's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its SIC code is 2836.